Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

236
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
236
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

196
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
196
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

380
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
380
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

196
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
196
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

121
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
121
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

223
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
223

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>In vitro</i> pharmacokinetics and pharmacodynamics of the diarylquinoline TBAJ-587 and its metabolites against <i>Mycobacterium tuberculosis</i>.

Frontiers in microbiology·2026
Same author

<i>In vitro</i> characterization of GSK2556286 in combination with bedaquiline and pretomanid against <i>Mycobacterium tuberculosis</i>.

Antimicrobial agents and chemotherapy·2026
Same author

Informing Sampling Design for Lung Distribution Studies Using a Pulmonary Population Minimal PBPK Model.

Clinical pharmacokinetics·2026
Same author

An Interactive Pharmacokinetic-Pharmacodynamic Framework to Evaluate Bedaquiline Dose Modifications in Adults With Tuberculosis.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Bedaquiline reloading strategies following interruptions during daily dosing.

Antimicrobial agents and chemotherapy·2026
Same author

Tuberculosis Disease Severity Assessment Using Clinical Variables and Radiology Enabled by Artificial Intelligence.

The Journal of infectious diseases·2026

Related Experiment Video

Updated: Sep 7, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K

Pharmacometrics in tuberculosis: progress and opportunities.

Justin J Wilkins1, Elin M Svensson2, Jacqueline P Ernest3

  • 1Occams Coöperatie, Amstelveen, The Netherlands.

International Journal of Antimicrobial Agents
|June 20, 2022
PubMed
Summary

Pharmacometrics, using mathematical models, optimizes tuberculosis (TB) drug dosing for better efficacy and safety. Advanced modeling techniques offer new opportunities for personalized TB treatment and drug interaction prediction.

Keywords:
Drug developmentModellingPharmacologyPharmacometricsSimulationTuberculosis

More Related Videos

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
08:54

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

7.8K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K

Related Experiment Videos

Last Updated: Sep 7, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K
Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
08:54

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

7.8K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K

Area of Science:

  • Pharmacometrics and mathematical modeling in infectious diseases.
  • Clinical pharmacology and drug development.
  • Computational modeling for tuberculosis treatment.

Background:

  • Tuberculosis (TB) is a major global health threat, particularly in underserved populations.
  • Pharmacometrics utilizes quantitative models to link drug exposure to effects (pharmacokinetics/pharmacodynamics).
  • Existing pharmacometric methods have improved population-level dosing for anti-TB drugs and antiretrovirals.

Purpose of the Study:

  • To review the current applications of pharmacometrics in tuberculosis pharmacotherapy.
  • To explore emerging opportunities for pharmacometrics to advance TB treatment.
  • To highlight the role of advanced modeling in optimizing anti-TB drug regimens.

Main Methods:

  • Review of existing literature on pharmacometric applications in TB.
  • Discussion of advanced modeling frameworks: physiologically based pharmacokinetics (PBPK), quantitative systems pharmacology (QSP), and machine learning.
  • Analysis of opportunities for in-silico drug-drug interaction quantification and personalized dosing.

Main Results:

  • Pharmacometric approaches have successfully informed population-level dosing strategies for TB and HIV co-infections.
  • Advanced modeling offers potential for predicting drug interactions and optimizing doses for special populations.
  • Understanding complex exposure-response relationships is crucial for multi-drug regimens.

Conclusions:

  • Pharmacometrics provides a robust framework for optimizing tuberculosis pharmacotherapy.
  • Future directions include leveraging advanced modeling for personalized dosing, drug interaction assessment, and novel regimen design.
  • Pharmacometrics is essential for improving the efficacy and safety of TB treatments globally.